What insurance does a clinical lab need for laboratory-developed tests (LDTs)?

The FDA finalized the LDT Final Rule in May 2024 bringing laboratory-developed tests under FDA medical device oversight. A federal district court vacated the rule in March 2025, leaving LDTs once again primarily regulated under CLIA. The FDA has indicated it intends to appeal or revise the regulatory approach. The result: regulatory uncertainty that affects how labs structure their insurance programs and how carriers underwrite LDT-related exposure.

During the vacatur period, LDT operators continue to face professional liability exposure for diagnostic accuracy (a missed cancer diagnosis is a live tort regardless of FDA framework) and increasingly face products liability questions when the LDT functions as a self-contained diagnostic system. The FDA framework, if reinstated, would add PMA/510(k) submission obligations and post-market surveillance requirements that materially change underwriting.

Professional liability (laboratory): primary coverage for diagnostic accuracy. Typical limits $1M-$5M, sized to test volume and complexity. CAP and COLA accreditation factor into underwriting; accredited labs typically achieve more favorable pricing.

Products liability with LDT extension: covers the LDT as a manufactured product if and when the FDA framework applies, or for product-style claims under state common law. Most modern medical-device products forms include LDT language, but verify wording explicitly. Limits $1M-$5M; higher for labs running LDTs in oncology or other high-severity indications.

Cyber liability and HIPAA breach response: PHI volume in clinical labs is substantial. Standalone cyber with notification expense, regulatory defense, ransomware, and HIPAA-specific breach response is essential. $3M-$10M typical, scaling with subject count and PHI sensitivity.

Commercial general liability, property (including instruments and equipment), crime/fidelity, commercial auto (for specimen pickup fleets), and workers compensation round out the program.

Hospital reference-lab service agreements typically require $1M/$3M professional liability minimum, $5M+ cyber for PHI volume, additional-insured wording for the hospital, primary and non-contributory, 30-day notice of cancellation, and current accreditation documentation (CAP, COLA, or applicable).

Bioanalytical contract labs serving pharma R&D operate under GLP and sponsor MSAs rather than CLIA + payor frameworks. Sponsor MSA insurance schedules typically require professional liability/E&O at $2M-$5M, cyber, products with appropriate extension if running LDTs or kits.

A Texas clinical lab at $10M revenue running LDTs typically pays $35,000-$80,000 annually for the core program. The variation reflects test complexity (oncology and germline genetic testing drive the upper end), accreditation status, prior claims history, and the volume of LDT-based testing as a share of total revenue.

Bioanalytical contract labs supporting pharma R&D run higher because of sponsor-MSA-driven professional liability and cyber requirements; $50,000-$150,000 at comparable revenue is typical.